1-20 of 30
Julia von Tresckow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Clinical Trials & Observations
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon Kater, Julie Dubois, Michael Gregor, Philipp Bernhard Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek
Journal: Blood
Blood (2024) 143 (25): 2588–2598.
https://doi.org/10.1182/blood.2023022564
Published: 2024
Includes: Supplemental data
Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia Von Tresckow, Anna Maria Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah R. Kilfoyle, Gunnar Juliusson, Caspar Da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindström, Philipp Bernhard Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4639.
https://doi.org/10.1182/blood-2023-188827
Published: 2023
Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna Maria Fink, Eugen Tausch, Christof Schneider, Sebastian Böttcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia Von Tresckow, Ursula Vehling-Kaiser, Clemens-Martin Wendtner, Kirsten Fischer, Karl Anton Kreuzer, Stephan Stilgenbauer, Philipp Bernhard Staber, Carsten Utoft Niemann, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 204.
https://doi.org/10.1182/blood-2023-188705
Published: 2023
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Moritz Furstenau, Valentin Goede, Julia Von Tresckow, Petra Langerbeins, Anna-Maria Fink, Henriette Huber, Eugen Tausch, Christof Schneider, Clemens-Martin Wendtner, Matthias Ritgen, Martin Dreyling, Lothar Müller, Lutz Jacobasch, Werner Heinz, Ursula Vehling-Kaiser, Liliya Sivcheva, Sebastian Böttcher, Peter Dreger, Thomas Illmer, Michael Gregor, Philipp Bernhard Staber, Stephan Stilgenbauer, Carsten Utoft Niemann, Arnon P. Kater, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2023) 142 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2023-178597
Published: 2023
Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Clinical Trials & Observations
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (11): 961–972.
https://doi.org/10.1182/blood.2023020013
Published: 2023
Includes: Supplemental data
Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Clinical Trials & Observations
Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (5): 446–459.
https://doi.org/10.1182/blood.2023019634
Published: 2023
Includes: Supplemental data
Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Moritz Furstenau, Yvonne Thus, Sandra Robrecht, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Julie M.N. Dubois, Julia Von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Michael Baumann, Thomas Noesslinger, Josien Regelink, Ellen C Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Simon Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Eric Eldering, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 842–845.
https://doi.org/10.1182/blood-2022-164786
Published: 2022
Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 834–836.
https://doi.org/10.1182/blood-2022-163245
Published: 2022
Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna L. Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 139 (9): 1318–1329.
https://doi.org/10.1182/blood.2021013208
Published: 2022
Includes: Supplemental data
Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Clinical Trials & Observations
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 139 (2): 177–187.
https://doi.org/10.1182/blood.2021010845
Published: 2022
Includes: Supplemental data
Journal Articles

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations

Clinical Trials & Observations
Paula Cramer, Eugen Tausch, Julia von Tresckow, Adam Giza, Sandra Robrecht, Christof Schneider, Moritz Fürstenau, Petra Langerbeins, Othman Al-Sawaf, Benedikt W. Pelzer, Anna Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (19): 1805–1816.
https://doi.org/10.1182/blood.2020010484
Published: 2021
Includes: Supplemental data
Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Anke Schilhabel, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Eugen Tausch, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Marinus H.J. Van Oers, Caspar Da Cunha-Bang, Christian H. Geisler, Stephan Stilgenbauer, Monika Brüggemann, Michael Hallek, Matthias Ritgen, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 72.
https://doi.org/10.1182/blood-2021-147729
Published: 2021
Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (Supplement 1): 71.
https://doi.org/10.1182/blood-2021-146161
Published: 2021
Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 2639.
https://doi.org/10.1182/blood-2021-147790
Published: 2021
Journal Articles

Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older

Florian Simon, Adam Giza, Sandra Robrecht, Anna-Maria Fink, Paula Cramer, Julia Von Tresckow, Moritz Fürstenau, Valentin Goede, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Clemens-Martin Wendtner, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 1552.
https://doi.org/10.1182/blood-2021-150698
Published: 2021
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, Julia Von Tresckow, MD, Anna-Maria Fink, MD, Gracia Braun, Sandra Robrecht, PhD, Can Zhang, PhD, Eugen Tausch, MD, Lothar Müller, MD, Wolfgang Knauf, MD, Othman Al-Sawaf, MD, Benedikt Pelzer, MD, Petra Langerbeins, MD, Kirsten Fischer, MD, Karl-Anton Kreuzer, MD, Matthias Ritgen, MD, Michael Kneba, MDPhD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Barbara Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-134827
Published: 2020
Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Julia Von Tresckow, Paula Cramer, Nisha De Silva, MBBS, MRCP, FRCPath, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Petra Langerbeins, MD, Anna- Maria Fink, MD, Othman Al-Sawaf, MD, Moritz Fürstenau, MD, Thomas Illmer, MD, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3046.
https://doi.org/10.1182/blood-2019-125895
Published: 2019
Journal Articles

Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation)

Paula Cramer, Julia von Tresckow, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Eugen Tausch, MD, Moritz Fürstenau, MD, Petra Langerbeins, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Clemens-Martin Wendtner, Barbara Eichhorst, Michael Kneba, Stephan Stilgenbauer, MD PhD, Michael Hallek
Journal: Blood
Blood (2018) 132 (Supplement 1): 694.
https://doi.org/10.1182/blood-2018-99-113155
Published: 2018